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ABSTRACT
The introduction of botulinum toxin more than 25 years ago for the management of paediatric lower and upper limb hyperto-
nia has been a major advance. BoNT-A as a part of multimodal treatment supports motor development and improves function 
disturbed by spasticity or hypertonia. 
The aim of this paper was to compare the efficacy and safety of three major BoNT-A preparations present on the market: abo-, 
inco-, and onaobotulinumtoxinA in the treatment of children with cerebral palsy. Based on an analysis of the available literature, 
all three preparations have been established to reduce hypertonia in the upper and lower extremities, with some conflicting 
evidence regarding function. There were no differences in treatment safety, with a low incidence of adverse events which were 
mostly temporary and mild. Any form of universal conversion ratio between all preparations is not recommended. 
Key words: botulinum toxin, cerebral palsy
(Neurol Neurochir Pol 2021; 55 (2): 158–164)
Introduction
Cerebral palsy (CP) has been described as: “a group of per-
manent disorders of the development of movement and posture 
causing activity limitations, which are attributed to nonprogres-
sive disturbances in the developing foetal or infant brain” [1]. 
CP is the main cause of disability among children and 
adolescents [2]. The majority of children with CP are affected 
by some form of hypertonia, of which spasticity is the most 
common [3]. Untreated spasticity leads to the development of 
contractures and bone deformities [4]. Other reasons for treat-
ing spasticity include improving mobility, facilitating the use 
of orthoses, improving posture and hand function, reducing 
pain from muscle spasms, and easing patient care/hygiene [5]. 
Over the past three decades, botulinum toxin type-A 
(BoNT-A) has become established as an important treatment 
modality for hypertonia in children with CP. After Koman et 
al. reported the first use of OnaBoNT-A in the treatment of 
spasticity associated with CP [6], the results of small-group 
studies that were published in the early 1990s showed that both 
OnaBoNT-A and AboBoNT-A were effective in the treatment 
of calf muscle spasticity resulting in tiptoeing [7, 8]. Over the 
following years, efficacy in the treatment of other muscles 
such as hamstrings or adductors has been presented [9, 10]. 
The biggest breakthrough in the BoNT-A therapy of chil-
dren with CP was the introduction of multi-level injections 
as part of a multimodal rehabilitation process which includes 
physiotherapy and orthoses among a range of other treatments. 
Such an integrated approach brings measurable results and 
changes the natural course of the disease [11, 12]. Subsequent 
years saw a rapid increase in the number of publications. In 
2010, the American Academy of Neurology and Child Neurol-
ogy Society published a Practice Parameter evaluating evidence 
from 148 studies; 15 studies encompassing the treatment of 
573 patients rose to the highest Class 1 level, and five studies rose 
to the Class 2 level [13]. Since then, a considerable amount of 
evidence has been published on this subject. Placebo controlled 
(PC) double blinded (DB) RCTs have shown significant im-
provements in different measures compared to placebo without 
major differences between toxin brands (Tab. 1). In 2019, the 
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Table 1. Randomised clinical trials (RCT), double blind (DB), single blind (SB), placebo controlled (PC), multicentre (MC), single centre (SC)







/number of assessed/  
/outcome measures  





Efficacy outcomes (only 
significant)/adverse 
events
Koman et al. 
1994 [8]
RCT; DB; PC: SC, 
MI/6 weeks/2/2 
(second after  
2 weeks)




PRS, ROM, no statistical 
analysis/AE-3 pts treated 
and 6 pts placebo arm
Sutherland et 
al.1999 [14]
RCT; DB; PC; SC/2/8 
weeks/2 (second 
after 4 weeks)
n = 19; 3D, EMG, ROM OnaBoNT-A/2–4 ND Ankle kinematics/ROM/
AE-no
Koman et al. 
2000 [15]
RCT; DB; PC, 
MC/2/12 weeks/2 
(second after 4 
weeks)
n = 108;  
1. PRS, .ROM, AROM, H-reflex, 
Blood serum antibodies
OnaBoNT-A/4–8/ 




PRS, AROM/AE-12 pts 
treated and 3 pts placebo 
arm
Ubhi et al. 2000 
[16]
RCT; DB; PC; 
SC/2/12 weeks/1
n = 40;  
1.2D 2.2D, ROM, GMFM
AboBoNT-A/15–25 GST, SOL, HMST, 
manual palpation 
Ankle kinematics, GMFM 
AE-6 pts treated and 1 pt 
placebo arm
Baker et al. 
2002 [17]
RCT; DB; PC; 
MC/4/16 weeks/1
n = 124; 
1. MTS 2. ROM, GMFM 
AboBoNT-A/10–30 GSC/manual pal-
pation 
ROM, MTS/AE 123/94 
pts treated and 20/31pts 
placebo arm, 24% related 
to treatment
Kanovsky et al. 
2004 [18]
RCT; DB; PC; 
MC/2/16 weeks/1
n = 52;  
1/2D; GMFM,
AboBoNT-A/ 30 GSC/manual pal-
pation 
Ankle kinematics/
AE- 30/10 pts treated and 
33/13 pts placebo arm
Ackman et al. 
2005 [19]
RCT; SB; PC; MC/3/
BTX-A/BTX-A+C/
PL+ C/56 /3 
n = 34;  
1/3D; 2/ROM, MAS, strength
OnaBoNT-A/4–8 GSC/ND ROM, MAS, 3D, strength – 
only BTX-A + GR/AE-3 pts 
treated and 6 pts placebo 
arm
Mall et al. 2000 
[10]
RCT; DB; PC; 
MC/2/12 weeks/1
n = 57;  
1. Knee to knee distance 2. 
ROM, MAS, GMFM, GAS
AboBoNT-A/30 ADD, HMST/ND Knee to knee distance, 
MAS, GAS, AE 9 pts treated 
and 3 pts placebo arm
Bjornson et al. 
2007 [20]
RCT; DB; PC; 
SC/2/24 weeks/1
n = 33;  
1.Spasticity/GMFM66 /88 
2.AS, ROM, EMG, E.C.I., 
strength, GMFM, GAS, COPM
OnaBoNT-A/12 GST/ES ROM/AE - 6 pts pain at 
injection site
Moore et al. 
2008 [21]
RCT; DB; PC; SC/2/2 
years/every 3 
months if clinically 
indicated
n = 124;  
1. GMFM, PEDI 
AboBoNT-A/10–30 GSC/manual pal-
pation 
No differences in long 
term follow-up/AE-208 in 
29 pts treated and 200 in 
27 pts placebo arm
Delgado et al. 
2016 [22]
RCT; DB; PC; 
MC/3/12
n = 228;  
1/MAS; 2/PGA, GAS, MTS)
AboBoNT-A/10–30 GST+SOL/USG MAS, PGA, MTS, GAS, 
AE – 144 pts. 2% treatment 
related
Corry et al. 
1997 [23]
RCT; DB; PC; 
SC/2/12weeks/1









Koman et al. 
2013 [24]
RCT; DB; PC; 
MC/2/27 weeks/1
n = 73; 1/UERS, MA, HC, MHC OnaBoNT-A/ 
1.4–12.5 
Shoulder, arm, fore-
arm, hand without 
spec; anatomical 
landmarks, USG
ROM (wrist only), MA
AE-5pts
Ferrari et al. 
2014 [25]
RCT; DB; PC; 
MC/2/24 weeks/1
n = 27 MAS, GAS, AHA, PEDI, 
AK
OnaBoNT-A/total 
dose < 300 U
PT, FCU, FCR, ADP, 




ES — electrostim; C — serial casting; GAS — Goal Attainment Scaling; GMFM — Gross Motor Function Measure; MAS — Modified Ashworth Scale; PRS — Physicians Rating Scale; ROM — Range of Motion; MTS 
— Modified Tardieu Scale; 3D — three-dimensional gait analysis; 2D — video gait analysis; PGA — Physician’s Global Assessment; G&R — grasp and release score; UERS — upper extremity rating scale; ND — no 
data; QUEST — Quality of Upper Extremity Skill Test; PEDI — Paediatric Evaluation of Disability Inventory; AK — ABILHAND-Kids; AE — adverse events; pts — patients
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Cochrane review of BoNT-A treatment of lower limb spastic-
ity in children by Blumetti et al. [26] included 31 randomised 
controlled trials assessing 1,508 participants. Studies compared 
BoNT-A in lower limb muscles to usual care or physiotherapy 
(PT) (14 studies), placebo or sham (12 studies), serial cast-
ing (four studies), or orthoses (one study). 20 studies used 
OnaBoNT-A and eight studies used AboBoNT-A. 
The authors concluded that children receiving BoNT-A 
injections tended to have improved gait pattern, ROM, sat-
isfaction with the outcome of treatment, and muscle tone, 
compared to their usual programme of care or PT, or a placebo. 
The quality of the evidence was very low for the comparison 
of BoNT-A versus usual care or physiotherapy; moderate for 
the comparison of BoNT-A versus placebo; moderate and 
low for the comparison of BoNT-A versus plaster casts; and 
very low for the comparison of BoNT-A versus orthoses. The 
authors did not mention any differences between different 
brands of toxins. 
In 2020, Farag et al. [27] published a systematic review of 
RCTs of BoNT-A treatment of upper limb spasticity in children 
with CP. 15 RCTs with a total of 499 participants were analysed. 
12 studies used OnaBoNT-A, and two used OnaBoNT-A and 
AboBoNT-A. The authors found evidence to support the use 
of BoNT-A as an adjunctive treatment to other modalities such 
as regular PT and occupational therapy (OT) with regard to 
the reduction of spasticity. Evidence to support its use as an 
adjunctive treatment to improve upper limb function or qual-
ity of life was insufficient. Any differences between brands of 
toxins were not reported. 
In 2012, Pin et al. [28] published a systematic review of 
the efficacy of BoNT-A in non-ambulant children with se-
vere CP: 19 studies were included. Indications for treatment 
were pain reduction, maintaining hip integrity, achieving 
functional changes, and goal attainment. A high percentage 
of participants in the studies showed positive changes. But 
most of the studies were of weak-to-moderate methodologi-
cal quality. The authors did not analyse brands of toxins used. 
BoNT-A is compared to other treatment modalities in most 
studies, but in clinical practice it is used as a complement to 
them. For this reason, the evaluation of its effectiveness as an 
adjunctive therapy seems interesting. In a review based on 
a ‘traffic light’ scheme, Novak et al. assessed 247 articles and 
398 intervention outcomes [29]. Interventions were classified 
with recommendations: green indicating “do it”, yellow “prob-
ably do it”, yellow “probably do not do it”, and red “clearly do 
not do it”. 14% (54 /398) of interventions achieved the level of 
green. Among them were: BoNT-A + OT for UE motor goals 
achievement (1–3 RCT), BoNT-A for tone reduction (UE + LE) 
(> 15 RCT), and BoNT + Casting for ROM (contractures) 
(4–15 RCT). BoNT-A + PT for mobility (4–15 RCT), BoNT-A 
+ PT for tone reduction, BoNT-A for ROM and Prevention of 
Hip Displacement (1–3 RCT), and BoNT-A + Hip Brace for 
Prevention of Hip Displacement (1–3 RCT) were rated yellow 
among 66% (264/398) of interventions. 
From the very beginning of BoNT-A’s use in paediatrics, 
the safety of treatment has been evaluated. The reported 
RCTs and analyses showed no differences between BoNT-A 
and placebo for adverse events (AEs). A systematic review 
of 20 randomised studies of botulinum toxin A, enrolling 
882 participants, reported 35 different AEs. [30]. 17 studies 
used OnaBoNT-A and four studies used AboBoNT-A. Accord-
ing to the authors, botulinum toxin type-A use was related to 
respiratory tract infection, bronchitis, pharyngytis, asthma, 
muscle weakness, urinary incontinence, falls, seizures, fever 
and unspecified pain. The authors concluded that botulinum 
toxin type-A has a good safety profile during the first months 
of use. However, the demonstration of a relationship between 
BoNT treatment and common childhood diseases and other 
common diseases in the population of children with CP may 
raise doubts. An interesting single centre report from 356 pa-
tients and 1,382 injection sessions indicated the overall rate of 
AEs for BoNT-A as being 3.3% for the sessions and 8.7% for 
the patients [31]. Both OnaBoNT-A and AboBoNT-A were 
injected. The data indicated that repeated BoNT-A injections 
were safe; AE were described as mild and were not associated 
with BoNT-A dose or brand. AE reactions were associated 
with GMFCS level and presence of epilepsy, but were mostly 
mild even for severely affected patients. 
The largest study on the efficacy and safety of AboBoNT-A 
treatment of children with CP is the retrospective study by 
Bakheit et al. [32]. Among 758 patients (1,594 sessions), the AE 
rate was 7%. However, in the group that received drug doses 
higher than 1,000 U / session or 30 U/kg body weight, this 
percentage was 22%. In a meta-analysis of the safety of Ona-
BoNT-A, 1,447 treated subjects were compared to a 914-strong 
control group [33]. The incidence of AE was approximately 
25% in patients treated with OnaBoNT-A, and 15% in the con-
trol group. The authors found a significantly higher incidence 
only for focal weakness in the treatment group. 
Interesting from the point of view of this review are studies 
in which both OnaBoNT-A and AboBoNT-A were used [9, 23, 
34, 35] and according to the authors preparations were used 
depending on availability. There were no differences between 
the preparations in terms of efficacy and safety, but none of 
the studies compared them directly. Two other papers have 
described the transition from OnaBoNT-A to AboBoNT-A 
for economic or administrative reasons [36, 37]. The authors 
found no differences in the efficacy or safety of the treatment. 
Tedroff et al. used a fixed 1:2 conversion ratio of OnaBoNT-A 
to AboBoNT-A. Dursun et al. based dosing decisions on the 
child’s individual presentation at that time. Carraro et al. 
[38] analysed the safety profile of IncoBoNT-A compared to 
OnaBoNT-A (ratio 1:1) in the treatment of lower limb spastic-
ity. The authors found no significant difference in frequency 
and type of AE. León-Valenzuela et al. looked at treatment 
safety of IncoBoNT-A with dose increase [39]. 69 children, 
mean age (SD) 8.3 (3.9) years, received IncoBoNT-A injections 
up to a maximum total dose of 600 U, 24 U/kg body weight. 
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191 injections were administered, with a dosing interval of 
6.0 (1.7) months. The mean (SD) total IncoBoNT-A dose 
increased from 191.7 (126.2) U at cycle 1 to 368.0 (170.1) U) 
at cycle 6. 74 AEs (37.5% of injections) were reported, the 
most frequent being injection pain (93.2% of AEs). 36.8% of 
participants were classified at GMFCS levels IV and V, without 
any safety concerns.
In recent years, manufacturer-sponsored, multicentre, 
international, Phase 3, RCTs have been conducted to assess 
the efficacy and safety of AboBoNT-A, OnaBoNT-A and 
IncoBoNT-A in lower and upper limb therapy. 
Until this article was published, only the results of the 
research on AboBoNT-A have been published as full articles; 
the results of the research on IncoBoNT-A and OnaBoNT-A 
have only been published as abstracts. In DB RCT and open-
label (OL) extension studies (NCT01249417/ NCT01251380), 
241 ambulatory children aged 2–17 with dynamic equinus were 
randomised to treatment with AboBoNT-A (10 or 15 U/kg/leg) 
or placebo injected into the gastrocsoleus. All children received 
AboBoNT-A in the OL phase. In DB RCT, treatment-related 
AEs (TRAE) were evenly distributed, with the highest rate (9%) 
in the placebo group. [22]. Repeated injections of AboBoNT-A 
in an open label study were generally well tolerated, with the 
number of patients experiencing TRAE varying from 16 in 
cycle 1 to 1 in cycle 4 . In both studies, the majority of TRAE 
were related to injection procedure and injection site pain was 
the most frequent. Significantly higher decreases of muscle 
hypertonia and spasticity (MAS, MTS), goal achievement 
(GAS), and overall global clinical impression (PGA) were 
demonstrated for the treatment groups [22, 40, 41]. In the dou-
ble-blind phase, AboBoNT-A significantly improved observa-
tional gait scale (OGS) total scores versus placebo at week 4, 
and continued to improve gait throughout the OL phase [42]. 
Importantly, a long-term therapeutic effect was demon-
strated: 74% of children treated did not require retreatment 
before week 16 or later, with 17.7% of patients not requiring 
retreatment before week 28 [40]. In DB, a repeat-cycle study 
(NCT02106351) saw 210 children, mean age (SD) 9y (4y 5mo), 
receive 2 U/kg, 8 U/kg, or 16 U/kg AboBoNT-A injections 
into UE alongside a home-exercise therapy programme. All 
children received 8 U/kg or 16 U/kg in cycles 2 to 4. At week 
6 of cycle 1, children in the 8 U/kg or 16 U/kg groups had 
significantly lower MAS scores versus the 2 U/kg group. There 
were no differences in GAS and PGA between groups. Thera-
peutic benefits were sustained during cycles 2 to 4. Muscular 
weakness was the only TRAE reported in at least one child/ 
/group [43]. In DB RCT (NCT0193411) 241 ambulatory chil-
dren (aged 2–17) with dynamic equinus were treated with three 
different doses (16, 12, 4 U/kg BW) of IncoBoNT-A in two sub-
sequent cycles. Overall, improvements in Ashworth Scale (AS) 
were observed in all IncoBoNT-A treatment groups at week 
4, without statistically significant differences. There were also 
no significant differences in re-injection time (cycle 2) [44]. 
From that group, 124 patients entered an open-label extension 
study (NCT01905683) and, together with 246 newly recruited 
patients (total 370), received up to four cycles of multilevel 
injections in LE and combined LE/UE muscles, with doses up 
to 20 U/kg (500 U) of IncoBoNT-A. 
The results showed a consistent improvement in plantar 
flexor hypertonia (AS) over long-term treatment [45]. The 
results of a similar to the previous PC DB RCT with OL 
extension study (NCT02002884), but focusing on UE spas-
ticity, were recently published [46]. In the MP, 350 patients 
aged 7.3 (4.4) years received 8, 6, 2 U/kg BW of IncoBoNT-A 
into upper limb, with additional lower-limb injections up to 
20 U/kg BW followed by three further injection cycles in OL 
extension study. In the DB, AS scores for the UE main clinical 
pattern improved significantly from baseline to week 4, with 
a significantly greater improvement in the 8-U/kg versus the 
2-U/kg dose group. Improvements were observed in all treated 
UE and LE clinical patterns and across all OL cycles. 
In analysis of pooled safety data from the three abovemen-
tioned LE and UE IncoBoNT-A studies, the authors reported 
2% of patients experienced AEs possibly related to the treat-
ment [47]. In DB PC RCT (NCT01603628), OnaBoNT-A 
8 U/kg/leg, 4 U/kg/leg, or placebo was injected into ankle 
plantar flexors of 384 patients OnaBoNT-A significantly de-
creased spasticity at weeks 4 and 6; it decreased by 1.1 (8 U/kg) 
and 1.0 (4 U/kg); OnaBoNT-A 8 U/kg significantly improved 
Clinical Global Impression (CGI) and improved measures 
of gait versus placebo [48]. Both OnaBoNT-A groups sig-
nificantly improved active and passive GAS. Moreover, the 
authors presented gait improvement measured by Edinburgh 
Visual Gait (EVG) score in the subset of patients. Dose 8 U/kg 
demonstrated statistical significance vs placebo at week 8 in 
the total score and select individual items (associated with 
foot stance and swing) [49]. 
As in previous studies, AboBoNT-A presented a good 
safety profile. Rates of patients reporting ≥ 1 AEs were 
similar across treatment groups. In DB PC RCT study 
(NCT01603602), 235 children (mean age 7.9 years; range 2–16) 
were injected with OnaBoNT-A 6 U/kg/side, 3 U/kg/side, or 
placebo into UE muscles; patients also received occupational 
therapy. Toxin groups demonstrated significant reductions 
of hypertonia and spasticity (MAS and MTS) compared to 
placebo, but did not differ significantly in mean CGI. Only the 
6 U/kg group demonstrated significant improvement in GAS 
passive goals at week 12 but not in active goals. OnaBoNT-A 
was well tolerated in both treatment groups, with no safety 
concerns [50]. 
To conclude, data from multicentre studies showing the 
efficacy and safety of BoNT treatment in almost 2,000 children 
with different hypertonia distributions, functional and health 
statuses could provide the final proof. 
Moreover, the authors presented a sustained effect of 
treatment not only in reducing hypertonia (MAS) but also in 
improving body function and activity. Interestingly, the dose 
ratio for higher dose groups in LE studies was 1.9/1/1 for 
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Abo/Inco/Ona BoNT-A respectively. The differences in dura-
tion of response need further analysis.
Summary
Based on the presented studies, we conclude that BoNT-
-A is safe in spasticity treatment in the majority of children 
with CP. 
In clinical practice, BoNT-A treatment should always be 
addressed to the patient for whom the reduction of hypertonia 
has the potential to provide a meaningful benefit in active 
function, hip integrity, comfort, or care. It is obligatory to use 
BoNT-A in conjunction with other treatment modalities such 
as OT, PT, orthotics or casting. 
There are no major differences between Abo, Inco and 
OnaBoNT-A both in PC DB RCT and observational studies. 
The low number of comparative studies does not provide 
evidence on exchange ratios. 
From the clinician’s point of view, different preparations 
of BoNT-A should be considered as distinct medications. All 
should be used while respecting individual country’s relavent 
SPCs. 
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